Abstract
ObjectivesIn our previous studies we reported a panel of 24 miRNAs that allowed discrimination between blood of lung tumor patients independent of the histological subtype and blood of healthy controls with an accuracy of 95.4% [94.9%-95.9%]. Here, we now separately analyzed the miRNA expression in blood of non-small cell lung cancer (NSCLC), including squamous cell lung cancer and adenocarcinoma, and small cell lung cancer (SCLC) patients.Patients and methodsIn total, we examined the expression levels of 1,205 miRNAs in blood samples from 20 patients from each of the three histological groups and determined differentially expressed miRNAs between histological subtypes and metastatic and non-metastatic lung cancer. We further determined the overlap of miRNAs expressed in each subgroup with the 24-miRNA signature of lung tumor patients.ResultsBased on a raw p-value < 0.05, only 18 blood-borne miRNAs were differentially expressed between patients with adenocarcinoma and with squamous cell lung carcinoma, 11 miRNAs between adenocarcinoma and SCLC, and 2 between squamous cell lung carcinoma and SCLC. Likewise, the comparison based on a fold change of 1.5 did not reveal major differences of the blood-borne miRNA expression pattern between NSCLC and SCLC. In addition, we found a large overlap between the blood-borne miRNAs detected in the three histological subgroups and the previously described 24-miRNA signature that separates lung cancer patients form controls. We identified several miRNAs that allowed differentiating between metastatic and non-metastatic tumors both in blood of patients with adenocarcinoma and in blood of patients with SCLC.ConclusionThere is a common miRNA expression pattern in blood of lung cancer patients that does not allow a reliable further subtyping into NSCLC or SCLC, or into adenocarcinoma and squamous cell lung cancer. The previously described 24-miRNA signature for lung cancer appears not primarily dependent on histological subtypes. However, metastatic adenocarcinoma and SCLC can be predicted with 75% accuracy.Electronic supplementary materialThe online version of this article (doi:10.1186/1476-4598-13-202) contains supplementary material, which is available to authorized users.
Highlights
Lung cancer is worldwide the leading cause of cancer related deaths in both men and women with estimated 1,608,055 (12.72%) new cases and 1,376,579 (18.2%) cancer deaths in 2008 ([1] available from: http://globocan. iarc.fr, accessed on 09/01/2013)
Overall miRNA expression in blood of lung cancer patients Previously, we reported a panel of 24 blood-borne miRNAs that allowed discrimination between lung tumor patients and healthy controls [24]
We analyzed the expression of blood-borne miRNAs in patients with Non-small cell lung cancer (NSCLC) or Small cell lung cancer (SCLC)
Summary
Lung cancer is worldwide the leading cause of cancer related deaths in both men and women with estimated 1,608,055 (12.72%) new cases and 1,376,579 (18.2%) cancer deaths in 2008 ([1] available from: http://globocan. iarc.fr, accessed on 09/01/2013). Non-small cell lung cancer (NSCLC) account for about 80% of all lung cancers and are further divided by their origin into adenocarcinoma (Adeno-Ca, about 40%), squamous cell carcinoma (sqCLC, about 30%) and large cell carcinoma (about 9%). Small cell lung cancer (SCLC) is far more aggressive than NSCLC and accounts for about 15% of all lung cancers. For early stage I and II NSCLCs, surgery is the treatment of choice As these two stages combined account for only 25 to 30% of all patients with lung cancer the most common treatment is systemic therapy (chemo- or targeted therapy) and/or radiotherapy [3,4,5]. Among NSCLCs, adenocarcinoma and squamous cell carcinoma differ with regards to the clinical management and the prognosis. Lung cancer diagnosis and subclassification is normally based on light microscopic criteria but an accurate diagnosis of histological lung cancer subtypes is often hampered by small tissue biopsies and high observer variability [7,8,9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
